Myoclonus
Conditions
Keywords
myoclonus, Etomidate, Dexmedetomidine
Brief summary
By observing the difference of plasma homovanillic acid concentrations and brain electrical consciousness monitoring Narcotrend index, study the possible mechanism of influencing Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia induction period.
Interventions
Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
DRUGnormal saline
Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
DRUGEtomidate
After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg. -Does not offer any other drugs within 5 min after completion of etomidate.
DRUGmidazolam，fentanyl，rocuronium
Anesthesia induction：Intravenous injection midazolam 0.03 \ 0.05 mg/kg, fentanyl 5 \ 8 g/kg, rocuronium 0.6 mg/kg
DRUGpropofol，remifentanil，cis atracurium
Anesthesia maintenance：Intravenous infusion of propofol 4 \ 6 mg/kg/h, remifentanil 0.1 \ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \ 0.1mg/kg
Sponsors
Tang-Du Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Sign the informed consent * American Society of Anesthesiologists (ASA)classification:class I\ II;undergoing elective surgery patients * Aged between 18 and 55, 49-67 kg weight * Body Mass Index（BMI）： 20-30 kg/m2 * Did not use any analgesic or sedatives drugs within 24 h pre-operation
Exclusion criteria
* Recently patients undergoing sedative drugs and antidepressant treatment * Serious vision, hearing impairment or other reasons can not communicate * Serious neurological disease, pregnancy, diseases of the cardiovascular system； * BMI is Less than the standard 80% or higher than the standard 120%
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| myoclonus level | when myoclonus occurs after emulsion injection is completed，assessed up to 5 minutes | * Level 0 ：no myoclonus happened; * Level 1 ：mild, tiny movement, one part of the body such as a finger or shoulder movement; * Level 2 ：moderate ,2 pieces of different muscle or slight movement of the muscle groups, such as face or legs; * Level 3 ：severely, 2 pieces or more muscle contracture intensity, such as fast outreach of limbs |
| Plasma homovanillic acid concentration（PHVA） | Measured when myoclonus occurs after emulsion injection is completed，assessed up to 5 minutes; if myoclonus does not appear,measured at 5 minutes after emulsion injection is completed. | — |
Secondary
| Measure | Time frame |
|---|---|
| Ramsay sedation score | 1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed； |
| Narcotrend index | 1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed； |
Outcome results
None listed